Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US11291645 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(4 months from now) | |
US11590097 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(4 months from now) | |
US11123321 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(4 months from now) | |
US9376505 | AM REGENT | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct, 2023
(4 months from now) | |
US7612109 | AM REGENT | Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes |
Feb, 2024
(8 months from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11433091 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(3 years from now) | |
US8895612 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(3 years from now) | |
US11478502 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(3 years from now) | |
US7754702 | AM REGENT | Methods and compositions for administration of iron |
Feb, 2028
(4 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Strength (NS) | Apr 28, 2024 |
New Patient Population (NPP) | Nov 19, 2024 |
Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient
Market Authorisation Date: 25 July, 2013
Treatment: Method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 46.7 kg by intravenously administering ferric carboxymaltose to provide at least 0.7 g o...
Dosage: SOLUTION;INTRAVENOUS
24
United States
6
European Union
5
Korea, Republic of
3
Canada
3
Denmark
3
Spain
3
Cyprus
3
Portugal
3
Hong Kong
2
Australia
2
Jordan
2
Japan
2
Norway
2
Slovenia
2
Germany
2
Brazil
2
China
1
Israel
1
New Zealand
1
Uruguay
1
Peru
1
Saudi Arabia
1
Malaysia
1
Austria
1
Russia
1
Poland
1
Mexico
1
Argentina
1
South Africa
1
Hungary
1
Taiwan
1
Lithuania
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic